BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35732409)

  • 21. Anaplastic large cell lymphoma, ALK-positive.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
    Shustov A; Soma L
    Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.
    Rigaud C; Knörr F; Brugières L; Woessmann W
    Best Pract Res Clin Haematol; 2023 Mar; 36(1):101444. PubMed ID: 36907641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful combination of crizotinib and hematopoietic stem cell transplantation in relapsed ALK-positive ALCL.
    Sun X; Fang X; Jiang Y
    Indian J Cancer; 2021; 58(1):108-111. PubMed ID: 33402581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brentuximab Vedotin and High-dose Methotrexate Administrated Alternately for Refractory Anaplastic Large-cell Lymphoma With Central Nervous System Disease.
    Mitsunobu T; Nishikawa T; Kusuda M; Nakagawa S; Kodama Y; Okamoto Y; Kawano Y
    J Pediatr Hematol Oncol; 2020 Aug; 42(6):e456-e458. PubMed ID: 31274669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Chen CH; Chen SW; Shen WL; Chen TY; Tsao CJ; Huang WT
    Int J Hematol; 2007 Feb; 85(2):105-7. PubMed ID: 17321986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
    Woessmann W; Peters C; Lenhard M; Burkhardt B; Sykora KW; Dilloo D; Kremens B; Lang P; Führer M; Kühne T; Parwaresch R; Ebell W; Reiter A
    Br J Haematol; 2006 Apr; 133(2):176-82. PubMed ID: 16611309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The biology and management of systemic anaplastic large cell lymphoma.
    Hapgood G; Savage KJ
    Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
    Domingo-Domènech E; Boumendil A; Climent F; Socié G; Kroschinsky F; Finel H; Vandenbergue E; Nemet D; Stelljes M; Bittenbring JT; Robinson S; Montoto S; Sureda A; Dreger P;
    Bone Marrow Transplant; 2020 Mar; 55(3):633-640. PubMed ID: 31695173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.
    Cleary JM; Rodig S; Barr PM; Shinagare AB; Clark JW; Shapiro GI; Armand P
    J Natl Compr Canc Netw; 2014 Mar; 12(3):323-6; quiz 326. PubMed ID: 24616538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of relapsed anaplastic large cell lymphoma with vinblastine monotherapy and allo-HSCT with reduced intensity conditioning regimen.
    Miyagaki S; Imamura T; Okumura Y; Ito I; Fujiki A; Osone S; Ishida H; Hosoi H
    Pediatr Int; 2015 Aug; 57(4):791-4. PubMed ID: 25847601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report.
    Harrer DC; Menhart K; Mayer S; Herr W; Reichle A; Vogelhuber M
    Front Oncol; 2020; 10():585830. PubMed ID: 33134180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent ALK-negative anaplastic large T-cell lymphoma presenting as necrotizing vasculitis.
    Nambudiri VE; Aboutalebi A; Granter SR; Saavedra A
    Am J Dermatopathol; 2013 Jun; 35(4):512-6. PubMed ID: 23291583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Allogeneic hematopoietic stem cell transplantation following treatment with brentuximab vedotin for refractory Hodgkin lymphoma].
    Yamane Y; Koda Y; Kohashi S; Kato J; Hashida R; Sakurai M; Toyama T; Kikuchi T; Okayama M; Kasahara H; Karigane D; Shimizu T; Okamoto S; Mori T
    Rinsho Ketsueki; 2017; 58(7):755-759. PubMed ID: 28781270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management.
    Bennani-Baiti N; Ansell S; Feldman AL
    Expert Rev Hematol; 2016; 9(2):137-50. PubMed ID: 26581318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course.
    Wehkamp U; Oschlies I; Nagel I; Brasch J; Kneba M; Günther A; Klapper W; Weichenthal M
    J Cutan Pathol; 2015 Nov; 42(11):870-7. PubMed ID: 26053561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease.
    Lawrence K; Berry B; Handshoe J; Hout D; Mazzola R; Morris SW; Saltman DL
    BMC Res Notes; 2015 Jul; 8():308. PubMed ID: 26187744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
    Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Blaise D; Peggs KS; Afanasyev B; Diez-Martin JL; Corradini P; Michonneau D; Robinson S; Gutiérrez García G; Bonifazi F; Yakoub-Agha I; Gülbas Z; Bloor A; Delage J; Esquirol A; Malladi R; Scheid C; El-Cheikh J; Ghesquières H; Montoto S; Dreger P; Sureda A
    Cancer; 2019 Jan; 125(1):90-98. PubMed ID: 30351488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
    Lowe EJ; Reilly AF; Lim MS; Gross TG; Saguilig L; Barkauskas DA; Wu R; Alexander S; Bollard CM
    Blood; 2021 Jul; 137(26):3595-3603. PubMed ID: 33684925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma.
    Mikles B; Levine J; Gindin T; Bhagat G; Satwani P
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):e85-7. PubMed ID: 23588340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.